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Abstract
Fibromyalgia (FM) is a complex disorder that affects up to 5% of the general population worldwide. Both
mitochondrial dysfunction and inflammation have been implicated in the pathophysiology of FM. We have
investigated the possible relationship between mitochondrial dysfunction, oxidative stress, and inflammation in
FM. We studied 30 women diagnosed with FM and 20 healthy women. Blood mononuclear cells (BMCs) from
FM patients showed reduced level of coenzyme Q10 (CoQ10) and mtDNA contents and high level of mito-
chondrial reactive oxygen species (ROS) and serum tumor necrosis factor (TNF)-alpha and transcript levels. A
significant negative correlation between CoQ10 and TNF-alpha levels (r = - 0.588; p < 0.01), and a positive cor-
relation between ROS and TNF-alpha levels (r = 0.791; p < 0.001) were observed accompanied by a significant
correlation of visual analogical scale with serum TNF-alpha and transcript levels (r = 0.4507; p < 0.05 and
r = 0.7089; p < 0.001, respectively). TNF-alpha release was observed in an in vitro (BMCs) and in vivo (mice) CoQ10
deficiency model. Oral CoQ10 supplementation restored biochemical parameters and induced a significant
improvement in clinical symptoms ( p < 0.001). These results lead to the hypothesis that inflammation could be a
mitochondrial dysfunction-dependent event implicated in the pathophysiology of FM in several patients indi-
cating at mitochondria as a possible new therapeutic target. Antioxid. Redox Signal. 18, 800–807.
Introduction
Fibromyalgia (FM) is a common chronic pain syndromeaccompanied by other symptoms such as fatigue, head-
ache, sleep disturbances, and depression, the pathophysio-
logical mechanisms of which have not yet been identified.
Although FM is diagnosed according to the classification
criteria established by the American College of Rheumatology
(ACR) (9), the diagnosis is not easy and may be frequently
overlooked; this is why new diagnostic markers in FM are
needed. Therefore, despite being a common disorder that
affects at least 5 million individuals only in the United States
(9), its pathogenic mechanism remains elusive. There are
some hypotheses and pilot studies suggesting that cytokines
may play an important role in FM (8), and correlation has
been observed between cytokines and several symptoms
common in FM (8). However, there are discrepant findings
related to whether pro-inflammatory and anti-inflammatory
cytokines are elevated or reduced in people with FM and
whether their levels correlate with the core symptoms of this
disorder (8).
Reactive oxygen species (ROS) have an established role in
inflammation and host defense, and are involved in the path-
ophysiology of several diseases including rheumatoid arthritis,
multiple sclerosis, and diabetes (1). Moreover, in addition to
the presence of oxidative stress, these diseases are also char-
acterized by deregulated inflammatory responses including,
but not limited to, pro-inflammatory cytokine production.
It is believed, that in cells undergoing aerobic metabolism,
the majority of ROS are produced as a byproduct of the
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mitochondrial electron transport chain (1,7). In this respect,
coenzyme Q10 (CoQ10), a small lipophilic molecule located in
the inner mitochondrial membrane, transfers reducing
equivalents from complexes I and II to complex III. It has been
widely demonstrated that CoQ10 is essential for mitochon-
drial chain efficiency, and evidence exists that it affects the
expression of genes involved in inflammatory pathways (6).
Recently, we demonstrated CoQ10 deficiency, mitochondrial
dysfunction, oxidative stress, and mitophagy in blood
mononuclear cells (BMCs) from FM patients (2).
This study examined the hypothesis that inflammation in
FM could be induced under conditions of mitochondrial
dysfunction and oxidative stress. We carried out these studies
with the aim of determining mitochondrial dysfunction,
oxidative stress, CoQ10 levels, in addition to serum tumor
necrosis factor (TNF)-alpha levels and mRNA expression
levels of TNF-alpha in BMCs from FM patients. Further, we
induced CoQ10 deficiency in BMCs from healthy controls to
evaluate TNF-alpha production, and analyzed the inflam-
mation activation in a mouse model of CoQ10 deficiency.
Finally, in FM volunteers, we studied the effects of oral CoQ10
supplementation on TNF-alpha levels and FM symptoms.
Results and Discussion
Mean age in the FM group was 43.8 – 13.1 years and in the
control group it was 44.9 – 10. Patient routine laboratory
tests yielded normal results (data not shown). The mean
duration of symptoms in the FM group was 8.2 – 4.4 years.
The mean tender point score in the FM group was 15.1 – 2.2
points (Table 1).
BMCs from FM patients show evidences
of mitochondrial dysfunction
Mitochondrial dysfunction has recently been proposed as a
relevant event in the pathogenesis of this disorder (2).
Mitochondria generate energy primarily in the form of elec-
trochemical proton gradient, which fuels ATP production, ion
transport, and metabolism. At the same time, mitochondria
are also the major source of ROS. Both complexes I and III,
along with CoQ10 leak electrons to oxygen (7). CoQ10 defi-
ciency has been associated with a variety of human disorders,
some of them caused by a direct defect of CoQ10 biosynthesis
genes or as a secondary consequence of other diseases (7).
Recent findings have shown that CoQ10 deficiency alters mi-
tochondria function andmitochondrial respiratory complexes
organization, leading to increased ROS generation and acti-
vation of mitochondrial transition pore, increasing autophagy
of dysfunctional mitochondria by mitophagy (2,7).
Since it has been suggested that CoQ10 levels could be a
useful biological marker of mitochondrial function (2,7),
we measured CoQ10 levels (Fig. 1A) in BMCs from healthy
controls and FM patients as a feature of mitochondrial dys-
function. BMCs from FMpatients showed a decrease of CoQ10
levels compared with controls (51% reduction of the average
controls value, Fig. 1A). Further, significant decrement in
mtDNA content in BMCs from FMpatients was also observed
(46.7% of the value found in the control group, Fig. 1B).
On one hand, it is known that mitochondrial dysfunction is
often associated with an induction of ROS production in mito-
chondria and on the other hand, oxidative stress has been
proposed as a relevant event in the pathogenesis of FM (2,4). To
assess the oxidative stress level, we determined mitochondrial
ROS in BMCs from FM patients and controls. On average, FM
patients showedhigher levels ofmitochondrial ROSproduction
in BMCs compared with control subjects (Fig. 1C).
Inflammation in FM patients is modulated
by mitochondrial dysfunction
Several hypotheses have been made around the etiological
origin of FM and its symptoms. Clinical studies have pro-
duced evidence that FM may be associated with immune
dysregulation of circulatory levels of pro-inflammatory
cytokines, affecting the neural dysfunction of pain-related
neurotransmitters (8). Cytokines, depending on their con-
centration, induce symptoms, such as fatigue, fever, sleep,
pain, and myalgia (8), all of which usually developed in FM
patients. Alterations in pro-inflammatory cytokine levels
have been observed in serum and biopsies of FM patients (8).
In addition, increased levels of IL-1Ra and IL-6 have been
found in the supernatants of cells from FMpatients in vitro (8).
To assess inflammation in FM patients, we determined TNF-
alpha levels in serum from controls and FM patients. FM
patients showed higher level of TNF-alpha in serum com-
pared with control subjects (Fig. 1D). Further, to corroborate
inflammation in FM patients we analyzed the expression of
tnf-alpha mRNA. Transcripts of tnf-alpha increased in BMCs
from FM patients (Fig. 1E). Recent evidence has shown the
possible involvement of ROS in inflammation suggesting that
mitochondrial ROS may be a novel therapeutic target for
inflammatory diseases. (1). In this respect, inflammation as a
consequence of oxidative stress and mitochondrial dysfunc-
tion has been indicated as the cause of many human diseases
Table 1. Characteristic Findings of Fibromyalgia
Patients and Control Group
Patients
N = 30
Controls
N = 20
Age (years) 43.8 – 13.1 44.9 – 10
Tender points 15.1 – 2.2 0
Duration of disease (years) 8.2 – 4.4 0
BMI (kg/m2) 25.8 – 3.3 24.6 – 2.1
VAS total score 6.9 – 0.8a 0.4 – 0.1
FIQ total score, range 0–80 56.1 – 11.1a 2.1 – 1.1
ap< 0.001.
BMI, Body Mass Index; FIQ, Fibromyalgia Impact Questionnaire;
VAS, Visual Analogical Scale.
Innovation
Inflammation has been indicated as being in the
pathophysiology of fibromyalgia (FM) in some patients,
and it has been suggested that oxidative stress and
mitochondria could be among the factors responsible for
development of inflammation. This is an interesting issue
that warrants consideration to design new experiments
to gain further insight into its potential therapeutic
applications, given that systemic antioxidant status is
an exogenously modifiable factor. The results described
in this article may serve as a new way for designing
experiments to better understand the influence of oxida-
tive stress on the development of FM and generate new
therapeutic strategies.
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[e.g. dyslipidemia, thrombosis, metabolic syndrome, diabetes,
macular degeneration, and neurodegenerative diseases such
as Alzheimer’s (1)]. Interestingly, we observed an important
negative correlation between CoQ10 and TNF-alpha levels
(r= - 0.588; p< 0.01), and a positive correlation between ROS
and TNF-alpha levels (r = 0.791; p< 0.001) (Fig. 2A, B). Also,
both TNF-alpha peptide and mRNA levels showed high
positive correlations with pain scale scores of FM patients
(Fig. 2C, D). These data suggest that high cytokine levels may
be involved in the pathophysiology of FM and underline
an important role of oxidative stress and mitochondrial
dysfunction in the inflammatory process in FM.
Induced CoQ deficiency leads to mitochondrial ROS
production and TNF-alpha synthesis
To verify the role of CoQ10 in the increase to TNF-alpha levels
observed in FM patients, we induced CoQ10 deficiency by in-
hibiting endogenous biosynthesis in BMCs from healthy con-
trols with P-aminobenzoate (PABA) treatment, a competitive
inhibitor of polyprenyl-4-hydroxybenzoate transferase (Coq2p)
(7), in vitro assay (Fig. 3A). PABA treatment affected oxidative
stress, inducing an increment of mitochondrial ROS levels
( p<0.001) (Fig. 3B). CoQ deficiency provoked an important
increment of TNF-alpha in the supernatant of cell cultures (Fig.
3C). Since CoQ10 is also an important antioxidant, we evaluated
the effect of treatment with CoQ10 and other antioxidants in the
in vitromodel of CoQ10 deficiency. BMCs were incubated with
PABA in the presence or absence of three antioxidants, CoQ10,
alpha-tocopherol (a-toc), and N-acetylcysteine (N-Acet). Mi-
tochondrial ROS and TNF-alpha production were then mea-
sured. CoQ10 attenuated ROS production ( p< 0.001) more
significantly than a-toc and N-acet ( p<0.05).
CoQ10 has been shown to have a connection with inflam-
mation: a significant negative correlation has been observed
between CoQ10 and pro-inflammatory markers in septic
shock patients (1). Moreover, expression profiling revealed
that CoQ10 influences the expression of inflammatory genes
suggesting that CoQ10 exerts anti-inflammatory properties
(6). This influence has been associated via NF-kappaB-
dependent gene expression. Immunohistochemical studies in
FM tissues revealed a stronger expression of NF-kappaB in
muscle (5), and TNF-alpha is an NF-kappaB-dependent pro-
inflammatory cytokine (1).
To study the role of CoQ10 in the pathogenesis of FM and
inflammatory process, and according to in vitro results, we
induced a partial depletion of CoQ10 in mice by sub-chronic
PABA administration. CoQ depletion might provoke an in-
crement of serum TNF-alpha in mice with respect to controls
(Fig. 4A). When compared with vehicle-treated controls,
PABA-injected mice showed an increase in serum TNF-alpha
levels (Fig. 4B), and, interestingly, also showed high levels of
hyperalgesia and reproduced a correlation between TNF-
alpha levels and pain. Finally, TNF-alpha levels showed an
important correlation with pain assayed in mice, (negative
correlation between TNF-alpha and time latency in hot place
test response, r= - 0.6187; p < 0.01).
Oral CoQ10 supplementation in FM patients reduced
TNF-alpha levels and improved clinical symptoms
According to our results, oxidative stress, mitochondrial
dysfunction, and also CoQ10 could play a role in the inflam-
matory response found in FM. CoQ10 may have two roles in
this pathological process: first of all, CoQ10 is a mitochondrial
cofactor with the potential to boost mitochondrial function
and, second, CoQ10 is a powerful free radical scavenger that
can mitigate lipid peroxidation and DNA damage caused by
oxidative stress (3). To study the possible effect of oral CoQ10
supplementation in inflammatory process and mitochondrial
FIG. 1. Coenzyme Q10 (CoQ10) levels, mitochondrial reactive oxygen species (ROS) production, and tumor necrosis
factor (TNF)-alpha levels in blood mononuclear cells (BMCs) from fibromyalgia (FM) patients and healthy control
individuals. (A) CoQ10 levels were measured by high-performance liquid chromatography, as described in Materials and
Methods. (B) Reduced mtDNA contents in BMCs from FM patients compared with healthy controls. (C) Mitochondrial ROS
production was analyzed in BMCs from controls and FM patients by flow cytometry as described in Material and Methods.
(D) Serum TNF-alpha levels in FM and control patients were measured as described in Material and Methods. (E) tnf-alpha
transcripts were analyzed by SYBR Green quantitative polymerase chain reaction as described in Materials and Methods.
Data represent the mean– SD of three separate experiments. *p < 0.001; **p < 0.05 between controls and FM patients.
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dysfunction of FM and evaluate the improvement in clinical
symptoms, eight volunteer FM patients were supplemented
with CoQ10. CoQ10 supplementation counteracted lipid per-
oxidation ( p < 0.001), and it restored CoQ10 levels andmtDNA
content in BMCs from FM patients ( p < 0.001). Interestingly,
TNF-alpha levels were significantly reduced together with a
marked improvement in FM clinical symptoms (Table 2).
Our patients, after oral CoQ10 supplementation showed an
important improvement in clinical FM symptoms, reduced
levels of TNF-alpha and lipid peroxidation, indicating once
again the possible role of CoQ10 in the pathogenesis of FM. In
other conditions of inflammation and oxidative stress, such as
in the case of strenuous exercise, CoQ10 supplementation
before exercise has been shown to decrease oxidative stress
and modulate inflammatory signaling, reducing the subse-
quent muscle damage (1). CoQ10 analogues, such as mito-
quinone, block transcription of inflammatory cytokines
involved in the mitochondrial ROS-dependent inflammatory
process (1).
Concluding Remarks and Future Directions
Most studies that have up to now examined the role of
inflammation in FM have been incomplete and contradictory
showing several discrepancies (8). However, according to
these results, the correlation between TNF-alpha, CoQ10, and
mitochondrial ROS levels may explain that inflammation in
several FM patients could depend on mitochondrial dys-
function, thus identifying a new subgroup of patients in FM.
Increased mitochondrial ROS in FM would result from
enhanced oxidative phosphorylation. Recently, we demon-
strated that oxidative stress could be implicated in the severity
of clinical symptoms in FM (2), therefore, antioxidant therapy
should be examined as a possible treatment in FM. Blockade
of ROS production by mitochondria would provide a new
therapeutic strategy to decrease symptoms in FM and other
inflammatory states. Moreover, CoQ10 treatment could be
used as an alternative therapy in FM and this should be the
aim of further studies. Further analysis involving doubled-
blind placebo-controlled clinical trials will be required to
confirm this observation. Indeed, our research group is cur-
rentlyworking in this direction, on the basis of the conclusions
of the exploratory work discussed in this article.
Notes
Ethical statements
Written informed consent and the approval of the ethical
committee of the University of Seville were obtained, ac-
cording to the principles of the Declaration of Helsinki.
FIG. 2. Correlations of: serum TNF-alpha versus CoQ10 (A), or versus mitochondrial ROS (B), and serum TNF-alpha and
transcript tnf-alphaversus pain in FMpatients (C andD).The correlationswere established by calculating correlation coefficients.
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Pain studies in mice were performed in accordance with
the European Union guidelines (86/609/EU) and Spanish
regulations for the use of laboratory animals in chronic ex-
periments (BOE 67/8509-12, 1988). All experiments were
approved by the local institutional animal care committee.
Patients
The study consisted of 30 women diagnosed with FM and
20 healthy women. Inclusion criteria were FM that had been
diagnosed in the previous 2 to 3 years, based on the current
ACR diagnostic criteria (9). Exclusion criteria were acute
FIG. 3. Induced CoQ deficiency in vitro leads to mito-
chondrial ROS production and TNF-alpha release. 1mM of
P-aminobenzoate (PABA) induced partial CoQ10 deficiency
(A), and high levels of mitochondrial ROS production, being
restored by antioxidants (B). CoQ deficiency provoked an
important increment of TNF-alpha in the supernatant of cell
cultures, counteracted by antioxidants (C). CoQ10 produced
a more significant protection than other antioxidants. Data
represent the mean– SD of three separate experiments.
*p< 0.001 between control and PABA; **p < 0.01 between
PABA with absence or presence of CoQ10; ***p < 0.05 between
presence of CoQ10 or presence of BHA or N-acetylcysteine.
FIG. 4. TNF-alpha release in a partial CoQ10 depletion
mice model. PABA was administered at a dose of 20mg/kg/
day for 15 days. (A) Levels of CoQ9 and CoQ10 measured in
BMCs from mice treated with vehicle or PABA (mammalian
species such as the mouse and the rat that have a relatively
short lifespan primarily contain CoQ9 and low levels of
CoQ10). Data represent the mean– SD of three separate ex-
periments. *p< 0.001 of CoQ9 and CoQ10 between vehicle or
PABA. (B) TNF-alpha levels were measured in serum from
mice treated with the vehicle or PABA. Data represent the
mean– SD of three separate experiments. *p< 0.001 between
vehicle or PABA. (C) Correlation of TNF-alpha serum levels
and pain in animal model. (n= 5 per group).
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infectious diseases in the previous 3 weeks; past or present
neurological, psychiatric, metabolic, autoimmune, allergy-re-
lated, dermal, or chronic inflammatory diseases; undesired
habits (e.g., smoking, alcohol, etc.); oral diseases (e.g., period-
ontitis); medical conditions that required glucocorticoid treat-
ment, use of analgesics, statin, or antidepressant drugs; past or
current substance abuse or dependence; and pregnancy or
current breastfeeding. Healthy controls had no signs or symp-
toms of FM andwere free of anymedication for at least 3 weeks
before the study began. All patients and controls had taken no
drugs or vitamin/nutritional supplements during the 3 weeks
prior to the collection of blood samples. However, before the
study, patients reported they used paracetamol on demand.
Clinical data were obtained from physical examination and
evaluated using the Fibromyalgia Impact Questionnaire (FIQ)
including visual analogue scales regarding general and diffuse
pain typical of FM (visual analogical scale [VAS]).
Animals and drug administration
Two groups (control and treated) of 5 six-week-old male
Swiss miceweighing 25–30 gweremaintained on a 12 h light/
dark cycle. PABA, a competitive inhibitor of polyprenyl-4-
hydroxybenzoate transferase (7), was dissolved in saline
(vehicle) and intra-peritoneally administered at a dose of
20mg/Kg/day for 15 days. Behavioral tests were performed
5 days after the first drug administration. After testing, mice
were anesthetized with CO2 and sacrificed by decapitation.
Blood samples were collected for immediate biochemical
analysis and BMCs were isolated.
BMC cultures
BMCs were purified from heparinized blood by isopycnic
centrifugation using Histopaque-1119 and Histopaque-1077
(Sigma Chemical Co.). BMCs were cultured at 37C in a 5%
CO2 atmosphere in RPMI-1640 medium supplemented
with L-glutamine, an antibiotic/antimycotic solution (Sigma
Chemical Co.), and 10% fetal bovine serum.
Induction of CoQ10 Deficiency
Partial CoQ10 deficiency was induced by inhibiting endoge-
nous biosynthesis in BMCs from healthy controls by treatment
with PABA (Sigma Chemical Co.), a competitive inhibitor of
polyprenyl-4-hydroxybenzoate transferase (7). To achieve this,
cells were cultured for 24h in the presence of 1mM PABA, or
alternatively PABA+ 10lM CoQ10, PABA+30lM a-toc, and
PABA+10mM N-Acet (Sigma Chemical Co.).
TNF-alpha levels
TNF-alpha levels in serum from control and patients, and
mice were assayed in duplicates by commercial ELISA kits
(ELISA, Biosource).
CoQ10 levels determination
CoQ9was used as an internal standard in human assay and
CoQ6 in mice assay. The cell samples were lysed with 1% SDS
and vortexed for 1min. A mixture of ethanol:isopropanol
(95:5) was added and the samples were vortexed for 1min. To
recover CoQ, 5ml of hexane was added and the samples were
centrifuged at 1000 g for 5min at 4C. The upper phases from
three extractions were recovered and dried on a rotator
evaporator. The lipid extract was suspended in 1ml of
ethanol, dried in a speed vac, and kept at - 20C. Samples
were suspended in a suitable volume of ethanol before high-
performance liquid chromatography (HPLC) injection. Lipid
components were separated by a Prominence Shymadzu
HPLC system (Shimadzu Scientific Instruments) equipped
with a Shimadzu Shim-pack XR-ODS column. CoQ levels
were analyzed using an ultraviolet SPD-20A detector.
Mitochondrial ROS production
Mitochondrial ROS generation in BMCs was assessed by
MitoSOX (Invitrogen/Molecular Probes), a red mitochon-
drial superoxide indicator. BMCs were incubated with 1 lM
MitoSox for 30min at 37C and washed twice with PBS. Cells
were analyzed by flow cytometry. To assay ROS production
with antioxidants, BMCs were incubated for 24 h with 10 lM
CoQ10, (Pharma Nord), 30lM a-toc, and 10mM N-Acet
(Sigma Chemical Co.).
Quantification of mtDNA
Nucleic acids were extracted from BMCs by standard cel-
lular lysis. The primers used were as follows: for mitochon-
drial DNA, mtF3212 (5¢-CACCCAAGAACAGGGTTTGT-3¢)
and mtR3319 (5¢-TGGCCATGGGTATGTTGTTAA-3¢) and
those for nuclear DNA for loading normalization, 18S rRNA
gene 18S1546F (5¢-TAGAGGGACAAGTGGCGTTC-3¢) and
18S1650R (5¢-CGCTGAGCCAGTCAGTGT3¢). Arbitrary units
were computed as the ratio between the optical density band
Table 2. Clinical Symptoms After Coenzyme Q10 Treatment
Pretreatment
N = 8
Post-treatment
N = 8
Controls
N = 20
Tender points 14 – 1.2 7.9 – 1.6a -
FIQ total score, range 0–80 56 – 3.2 32.9 – 2.2a 2.1 – 1.1
VAS, range 0 10 6.6 – 0.5 3.6 – 0.6a 0.4 – 0.1
CoQ10 (pmol/mgprotein) 102.6 – 21.9 201.9– 32.1a 209.6– 3.5
mtDNA content 0.4 – 0.1 0.9 – 0.1a 1 – 0.09
LP in BMCs (nmol/million cells) 25.1 – 8.1 9.3 – 3.2a 6.8 – 1.9
TNF-alpha (pg/ml) 82.5 – 11.2 31.9 – 9.9a 32.6 – 0.05
Values are mean– SD.
ap< 0.001 between pre- and post-treatment.
CoQ10, Coenzyme Q10; mtDNA, mitocondrial DNA; LP, lipid peroxidation; BMCs, blood mononuclear cells; TNF, tumor necrosis factor.
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corresponding to the mitochondrial DNA studied in the 20–
30th cycle and that of nuclear DNA in the 15th amplification
cycle. One unit was considered to be the ratio corresponding
to the control patient.
Lipid peroxidation
Lipid peroxidation in cells was determined by analyzing
the accumulation of lipoperoxides using a commercial kit
from Cayman Chemical. TBARS are expressed in terms of
malondialdehyde levels.
Real-time quantitative polymerase chain reaction
The expression of tnf-alpha gene was analyzed by SYBR
Green quantitative polymerase chain reaction using mRNA
extracts of BMCs from patients and controls. The thermal
cycling conditions used were as follows: denaturation at 95C
for 20 s, alignment at 54C for 20 s, and elongation at 72C for
20 s, for 40 cycles. Tnf-alpha primers were as follows: 5¢-GCT
GCA CTT TGG AGT GAT CG-3¢ (forward) and 5¢-CTT ACC
TAC AAC ATG GGC TAC AG-3¢ (reverse). As an internal
control, we used beta-actin primers; forward: 5¢-CCA GAT
CAT GTT TGA GAC C-3¢ and reverse: 5¢-ATG TCA CGC
ACG ATT TCC C-3¢. All reactions were performed in dupli-
cate. Reaction mixtures without RNA were used as negative
controls in each run.
Behavior studies of pain sensibility in mice
For the hot-plate test, a glass cylinder (16 cm high and 16 cm
in diameter) was used to retain the mice on the heated surface
of the plate, whichwas kept at the temperature of 45C– 0.5C,
50C– 0.5C, or 52.5C– 0.5C. The time latency for paw-
licking was measured. The cut-off for licking responses was
30 s. For the tail flick test, a thermostatic water bathwas kept at
a temperature of 48C– 0.5C. The time latency for tail reflex
was measured. The cut-off for responses was 15 s.
Oral CoQ10 supplementation
Eight volunteer patients were supplemented with CoQ10
(purchased from Pharma Nord), in soft gel capsules for
3 months (300mg/day CoQ10 divided into three doses). After
3 months of treatment, heparinized blood samples were
collected after 12-h fasting and 24 h after the last dose, and
clinical symptoms were evaluated. The CoQ10 formulation
consisted of soft gelatin capsules containing 100mg of ubi-
quinone emulsifiedwith diglyceryl monooleate, beeswax, soy
lecithin, and canola oil.
Statistical analysis
Data in figures are given as mean– SD. Data between dif-
ferent groups were statistically analyzed by using analysis of
variance (ANOVA) on Ranks with Sigma Plot and Sigma Stat
statistical software (SPSS for Windows, 19, 2010, SPSS Inc.).
For cell-culture studies, Student’s t test was used for data
analyses. A value of p< 0.05 was considered significant. To
compare the behavioral results from animals treated with
vehicle alone or with PABA a two-way variance (ANOVA)
analysis was used. Statistical analyses included Pearson’s
correlations between CoQ10 levels and mitochondrial ROS
levels in BMCs compared with TNF-alpha, and between VAS
pain compared with serum TNF-alpha peptide and mRNA.
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Abbreviations Used
a-toc¼ alpha-tocopherol
ACR¼American College of Rheumatology
ANOVA¼ analysis of variance
BMCs¼ blood mononuclear cells
BMI¼Body Mass Index
CoQ10¼Coenzyme Q10
FM¼fibromyalgia
HPLC¼high-performance liquid chromatography
MDA¼malondialdehyde
N-acet¼N-acetylcysteine
PABA¼P-aminobenzoate
ROS¼ reactive oxygen species
TNF¼ tumor necrosis factor
VAS¼visual analogical scale
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